Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Candice Swanepoel wows in a shimmering black flared jumpsuit as she joins ab
Met Gala 2024: Doja Cat boldly dons massive wet T
More GOP states challenge federal rules protecting transgender students
How Robert F. Kennedy Jr. could make the first debate stage
Big Ten women's basketball schedule brings USC, UCLA to conference's easternmost schools
What to know about the Penske scandal that has rocked IndyCar
Unexpected Michigan Senate race could determine control of the chamber
I'm a cruise ship worker...these are the FIVE things smart passengers always do onboard
Closing prices for crude oil, gold and other commodities
China vows to actively promote restoration of int'l flights
Georgia governor signs new election changes into law